Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
or
Menu

Cerus Corp (CERS)

[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Quote Overview for [[ item.sessionDateDisplayLong ]]
[[ rowChartData.labelLow ]]
[[ rowChartData.lowPriceFormatted ]]
[[ rowChartData.lowPrice ]]
[[ rowChartData.labelHigh ]]
[[ rowChartData.highPriceFormatted ]]
[[ rowChartData.highPrice ]]
since [[ rowChartData.lowDate ]]
since [[ rowChartData.highDate ]]
[[ fieldTitles[key] ]] [[ value ]] [[ value ]]
Realtime quote and/or trades are not sourced from all markets.

Fundamentals

See More
  • Market Capitalization, $K 715,086
  • Shares Outstanding, K 135,690
  • Annual Sales, $ 51,330 K
  • Annual Income, $ -60,590 K
  • 36-Month Beta 1.54
  • Price/Sales 15.15
  • Price/Cash Flow N/A
  • Price/Book 8.47

Analyst Rating / Earnings Estimates

Current Rating
See More
Strong Buy
Based on 5 analysts offering recommendations.
Earnings Estimates - Current Qtr 12/31/18
See More
  • Average Estimate -0.10
  • Number of Estimates 1
  • High Estimate -0.10
  • Low Estimate -0.10
  • Prior Year -0.10
  • Growth Rate Est. (year over year) unch

Price Performance

See More
Period Period Low Period High Performance
1-Month
5.17 +2.51%
on 11/12/18
7.06 -24.93%
on 10/18/18
-0.69 (-11.52%)
since 10/12/18
3-Month
5.17 +2.51%
on 11/12/18
7.81 -32.14%
on 08/31/18
-1.86 (-25.98%)
since 08/13/18
52-Week
3.35 +58.21%
on 12/29/17
8.05 -34.16%
on 08/03/18
+1.72 (+48.04%)
since 11/13/17

Most Recent Stories

More News
Report: Developing Opportunities within Lexicon Pharmaceuticals, Cray, RCI Hospitality, Sanmina, Diamond Offshore Drilling, and Cerus -- Future Expectations, Projections Moving into 2018

In new independent research reports released early this morning, Fundamental Markets released its latest key findings for all current investors, traders, and shareholders of Lexicon Pharmaceuticals, Inc....

LXRX : 8.41 (+0.36%)
CRAY : 24.27 (+1.68%)
RICK : 26.01 (-0.54%)
SANM : 25.11 (+1.66%)
DO : 12.88 (-6.53%)
CERS : 5.30 (+0.57%)
Cerus to Present at the 2018 Canaccord Genuity Medical Technologies & Diagnostics Forum

Cerus Corporation (Nasdaq:CERS) announced today that William 'Obi' Greenman, Cerus' president and chief executive officer, and Vivek Jayaraman, Cerus' chief commercial officer, are scheduled...

CERS : 5.30 (+0.57%)
The Global Infection Control Market is Set to Grow as the U.S. Population Ages

According to MarketsandMarkets, the global infection control market is expected to reach USD 21.06 Billion by 2022, after having grown from USD 15.35 Billion in 2017. The market is also expected to have...

CTSO : 9.54 (-1.45%)
MD : 39.73 (-0.92%)
OMI : 8.96 (-2.93%)
CERS : 5.30 (+0.57%)
PCTL : 0.3200 (+22.46%)
Cerus to Present at the 2018 Stephens NY Investment Conference

Cerus Corporation (Nasdaq:CERS) announced today that William 'Obi' Greenman, Cerus' president and chief executive officer, and Kevin Green, Cerus' vice president, finance and chief financial...

CERS : 5.30 (+0.57%)
Cerus: 3Q Earnings Snapshot

CONCORD, Calif. (AP) _ Cerus Corp. (CERS) on Thursday reported a loss of $14.2 million in its third quarter.

CERS : 5.30 (+0.57%)
Cerus Corporation Reports Third Quarter 2018 Results

Cerus Corporation (Nasdaq: CERS) announced today financial results for the third quarter ended September 30, 2018.

CERS : 5.30 (+0.57%)
Cerus Receives FDA Breakthrough Device Designation for Pathogen-Reduced Cryoprecipitate

Cerus Corporation (Nasdaq:CERS) announced today that the U.S. Food and Drug Administration (FDA) has granted Breakthrough Device designation for the Company's pathogen-reduced cryoprecipitate...

CERS : 5.30 (+0.57%)
Data Projects the Global Medical Device Technologies Market to Grow $674 Billion by 2022

According to a report published by BCC Research, the global medical device technologies market is expected to grow from USD 521.2 Billion in 2017 to USD 674.5 Billion by 2022. The market is also set to...

CTSO : 9.54 (-1.45%)
AMDA : 0.29 (+7.41%)
CRMD : 1.10 (-9.09%)
MEDD : 0.0071 (-5.33%)
CERS : 5.30 (+0.57%)
PCTL : 0.3200 (+22.46%)
Cerus to Release Third Quarter 2018 Results on November 1, 2018

Cerus Corporation (Nasdaq:CERS) announced today that its third quarter results will be released on Thursday, November 1, 2018, after the close of the stock market. The company will host a...

CERS : 5.30 (+0.57%)
Detailed Research: Economic Perspectives on Cerus, AdvanSix, Spark Therapeutics, Imperva, Central Garden & Pet, and Francesca's -- What Drives Growth in Today's Competitive Landscape

In new independent research reports released early this morning, Fundamental Markets released its latest key findings for all current investors, traders, and shareholders of Cerus Corporation (NASDAQ:CERS),...

ONCE : 42.67 (+2.47%)
IMPV : 55.89 (+0.09%)
FRAN : 2.69 (-8.81%)
CENTA : 28.96 (-1.06%)
CERS : 5.30 (+0.57%)
ASIX : 26.82 (+0.37%)

Barchart Technical Opinion

The Barchart Technical Opinion rating is a 100% Sell with a Strongest short term outlook on maintaining the current direction.

Longer term, the trend strength is Maximum. Long term indicators fully support a continuation of the trend.

The market is in highly oversold territory. Beware of a trend reversal.

See More Share

Trade CERS with:

Business Summary

Cerus Corporation is developing medical products based on a platformtechnology that prevents nucleic acid replication. The company's initialapplication of this technology is the development of systems to inactivateviruses, bacteria and other pathogens in blood components used for transfusion. The company...

See More

Key Turning Points

2nd Resistance Point 5.58
1st Resistance Point 5.44
Last Price 5.30
1st Support Level 5.22
2nd Support Level 5.14

See More

52-Week High 8.05
Fibonacci 61.8% 6.25
Fibonacci 50% 5.70
Last Price 5.30
Fibonacci 38.2% 5.15
52-Week Low 3.35

See More

Add Data Columns to this Table
Learn about our Custom Views
Want to use this as
your default charts setting?
Learn about our Custom Templates
Switch the Market flag
above for targeted data.
Open the menu and switch the
Market flag for targeted data.
Get Streaming Chart Updates
Switch your Site Preferences
to Interactive Chart
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.

Free Barchart Webinar